9BR3
Crystal structure of p53 Y220C mutant in complex with PC-10709
This is a non-PDB format compatible entry.
Summary for 9BR3
| Entry DOI | 10.2210/pdb9br3/pdb |
| Descriptor | Cellular tumor antigen p53, 2-{3-[4-(methanesulfonyl)-2-methoxyanilino]prop-1-yn-1-yl}-N-(1-methylpiperidin-4-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine, ZINC ION, ... (4 entities in total) |
| Functional Keywords | p53, y220c mutant, ligand, transferase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 2 |
| Total formula weight | 50577.94 |
| Authors | Abendroth, J.,Lorimer, D.D.,Vu, B.,Tanaka, N. (deposition date: 2024-05-10, release date: 2025-03-26, Last modification date: 2025-06-18) |
| Primary citation | Puzio-Kuter, A.M.,Xu, L.,McBrayer, M.K.,Dominique, R.,Li, H.H.,Fahr, B.J.,Brown, A.M.,Wiebesiek, A.E.,Russo, B.M.,Mulligan, C.L.,Yang, H.,Battaglia, J.,Robell, K.A.,Thomas, D.H.,Huang, K.S.,Solovyov, A.,Greenbaum, B.D.,Oliner, J.D.,Davis, T.W.,Dumble, M.L.,Johnson, M.L.,Xiong, S.,Yang, P.,Lozano, G.,Fellous, M.M.,Vu, B.T.,Schram, A.M.,Levine, A.J.,Poyurovsky, M.V. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discov, 15:1159-1179, 2025 Cited by PubMed Abstract: Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. Here, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing anti-proliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild type p53 program. These compounds demonstrate potent anti-tumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational Phase 2 clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. PubMed: 39945593DOI: 10.1158/2159-8290.CD-24-1421 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.9 Å) |
Structure validation
Download full validation report
